Literature DB >> 12629271

Reversible angiotensin II-mediated albuminuria in rat kidneys is dynamically associated with cytoskeletal organization.

Steven P Clavant1, Josephine M Forbes, Vicki Thallas, Tanya M Osicka, George Jerums, Wayne D Comper.   

Abstract

Angiotensin II (ANG II) is intimately involved in normal renal function, and is estimated to exist at a normal physiological range of 6-10 nM within the renal tubules. The potential role that intrarenal ANG II may play in renal disease was assessed by perfusing isolated rat kidneys with or without excess intratubular levels of ANG II, which may mimic changes in the intrarenal RAS under pathological conditions. The effects of increased systemic ANG II were also determined by infusing rats with ANG II by osmotic pump. In isolated perfused kidneys, ANG II significantly and specifically increased the fractional clearance of albumin to clinical levels, as determined by using radiolabelled albumin. This effect was reversible, as removing ANG II from the perfusate caused the albumin fractional clearance to decrease to pre-ANG II exposure levels. The increase in fractional clearance of albumin was not correlated with renal hemodynamic changes, nor glomerular permeability alterations as measured by the fractional clearance of 36 A Ficoll and immunoglobulin G. Immunochemical analysis using anti-alpha-tubulin antibody of perfused kidney sections revealed that ANG II caused a marked disruption of tubular epithelial cytoskeletal components, through disassembly and reorganization of alpha-tubulin. This disruption was reversible. In vivo, osmotic pump delivery of ANG II at less potent dosage caused a proteinuria (Biuret) and an albuminuria (radioimmunoassay) in rats, from as early as 2 days after pump implantation. These results demonstrate that ANG II may reversibly induce clinical levels of albuminuria. These data point to an important role for renal tubules and the intratubular lumen concentrations of ANG II in the renal processing of albumin. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12629271     DOI: 10.1159/000068528

Source DB:  PubMed          Journal:  Nephron Physiol        ISSN: 1660-2137


  6 in total

Review 1.  Antiproteinuric effect of RAS blockade: new mechanisms.

Authors:  Markus Lassila; Mark E Cooper; Karin Jandeleit-Dahm
Journal:  Curr Hypertens Rep       Date:  2004-10       Impact factor: 5.369

2.  Congenital nephrotic syndrome responsive to angiotensin-converting enzyme inhibition.

Authors:  Rajasree Sreedharan; Detlef Bockenhauer
Journal:  Pediatr Nephrol       Date:  2005-06-18       Impact factor: 3.714

Review 3.  Blood pressure lowering for the prevention and treatment of diabetic kidney disease.

Authors:  Merlin C Thomas; Robert C Atkins
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Where does albuminuria come from in diabetic kidney disease?

Authors:  Wayne D Comper; Leileata M Russo
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

Review 5.  Clinical therapeutic strategies for early stage of diabetic kidney disease.

Authors:  Munehiro Kitada; Keizo Kanasaki; Daisuke Koya
Journal:  World J Diabetes       Date:  2014-06-15

6.  Combining Neprilysin Inhibitor With AT2R Agonist Is Superior to Combination With AT1R Blocker in Providing Reno-Protection in Obese Rats.

Authors:  Elizabeth Alana Gray; Sanket N Patel; Peter A Doris; Tahir Hussain
Journal:  Front Pharmacol       Date:  2022-02-07       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.